

Plasma Histamine Levels during Induction of Anesthesia with Propofol in Dogs

Hiomasa MITSUHATA and Reiju SHIMIZU

We examined a property of emulsion formation of propofol (ICI 35868) to release histamine into circulating plasma in dogs. Plasma histamine was measured with radioimmunoassay before (baseline), and 1, 5 and 10 min after the administration of 15 mg·kg⁻¹ propofol. There were no significant differences between the plasma histamine levels at 1, 5 and 10 min after the administration of propofol and the baseline level. We conclude that the emulsion formation of propofol of 15 mg·kg⁻¹ does not release histamine during induction of anesthesia in dogs. (Key words: propofol, dog, histamine, intravenous anaesthetic)

(Mitsuhata H, Shimizu R: Plasma histamine levels during induction of anesthesia with propofol in dogs. *J Anesth* 7: 206–209, 1993)

Incidence of anaphylactoid reactions occurring during anesthesia is one operation per 5,000–20,000 episodes of general anesthesia¹. These reactions were mediated via non-immunological or immunological mechanisms. Non-immunological mechanism is commonly related to direct histamine release². Recently propofol (ICI 35868) has been widely used as an induction anaesthetic^{3,4,5}. Initially it was prepared as a 1% solution in Cremophor EL, which have been reported to produce anaphylactoid reaction mediated by histamine release⁶, and then this formation was withdrawn from clinical use. Propofol was therefore reformed as a 1% w/v solution in an aqueous emulsion consisting of 10% soya bean oil, 2.25% glycerol and 1.2% purified egg phosphatide. We evaluated a property of this emulsion formation

of propofol to release histamine into circulating plasma during induction of anesthesia in dogs.

Materials and Methods

Seven mongrel dogs (12–23 kg body weight) were used. Approval was obtained from the institutional committee on animal investigations. Venous blood were taken through a catheter placed in a vein of the forearm before (baseline), and 1, 5 and 10 min after the administration of propofol of 15 mg·kg⁻¹, given over 30 sec. The blood was transferred immediately into an iced tube containing ethylenediaminetetraacetic acid (EDTA, 2Na), and centrifuged at 1200g for 30 min at 4°C. The plasma obtained was refrigerated at –80°C until histamine was assayed. The plasma histamine levels were measured by radioimmunoassay, using HISTAMINE RADIO-IMMUNOASSAY KIT® (Immunotech S.A. Marseille, France, Eiken, Tokyo).


The statistical analysis was performed by using one-way analysis of variance (ANOVA), followed by Fisher

Department of Anesthesiology Jichi Medical School, Tochigi-ken, Japan

Address reprint requests to Dr. Mitsuhata: Department of Anesthesiology, Jichi Medical School, 3311-1, Yakushiji, Minamikawachi, Kawachi-Gun, Tochigi-ken, 329-04 Japan

Fig. 1. Plasma histamine concentration ($\text{ng}\cdot\text{ml}^{-1}$) before and 1, 5, 10 min after administration of propofol of $15\text{ mg}\cdot\text{kg}^{-1}$ in dogs.

Open circles and vertical lines represent mean and SE, respectively.



PLSD test for paired data. A P values of < 0.05 was considered statistically significant.

Results

Changes in plasma histamine concentrations before and 1, 5 10 min after the administration of propofol in each dog and means with standard errors are shown in figure 1. Plasma histamine levels at 1, 5 and 10 min showed no significant differences compared with the level of baseline in mean values of 7 dogs. There were no significant differences among the means measured at 4 periods of time.

Discussion

Histamine is very easily released from blood cells into plasma during preparations for the histamine assay⁷. We withdrew venous blood and handled it extremely carefully to exclude mechanical release of histamine. The radioimmunoassay used in the present study can detect the plasma histamine level of $0.1\text{ ng}\cdot\text{ml}^{-1}$. This is more sensitive than radioenzymatic assay used in the earlier studies on plasma histamine after the propofol administration^{9,10,11}.

The plasma histamine concentration did not increase at least for 15 min after the administration of propofol compared with baseline. Only one dog showed high plasma histamine levels before and 10 min after the admin-

istration of propofol. These two high levels probably included mechanically-released histamine, because the levels at 1 and 5 min remained low.

Our results revealed that propofol did not induce direct histamine release after the administration of propofol of $15\text{ mg}\cdot\text{kg}^{-1}$. Glen and Hunter also reported that histamine concentration remained at a baseline value of $12\text{--}17\text{ ng}\cdot\text{ml}^{-1}$ for 20 min in dogs given the emulsion formation of propofol (ICI 35868)⁹. The administered doses in this study was 6 to 7.5 times as large as induction dose required in human adults, usually 2 to $2.5\text{ mg}\cdot\text{kg}^{-1}$ ⁴, and a dog is more susceptible to Cremophor, which has the direct histamine-releasing property than a man, pig or rabbit¹². Therefore, it is less likely that the emulsion formation of propofol (ICI 35868) may produce direct histamine release in man. The evidence that propofol did not increase histamine levels *in vivo* and *in vitro* are proved by other authors^{9-11,13-15}.

The patient with thiopentone anaphylaxis has been reported to be induced safely with propofol¹⁶. Although in clinical and experimental study propofol is thought to be a safe induction anaesthetic in regard to direct histamine-release, 2 cases with IgE-mediated anaphylaxis induced by propofol^{17,18} and anaphylactoid reaction induced by propofol-atracurium¹⁹

are reported. It is possible that anaphylaxis or anaphylactoid reaction to even propofol without property of direct histamine release would occur. Because muscle relaxants such as vecuronium and pancuronium which have a poor histamine-releasing property rarely cause severe clinical anaphylaxis, there is a poor correlation between the histamine-releasing properties of drugs and their likelihood of producing a severe adverse reaction². Therefore, propofol as well as any other drug without the histamine-releasing property should be administered in consideration of the likelihood of anaphylaxis or anaphylactoid reaction.

Acknowledgments: The authors thank Imperial Chemical Industries for supplies of drug, propofol, ICI 35 868.

(Received Mar. 30, 1992, accepted for publication Aug. 7, 1992)

References

- Schatz M, Fung DL: Anaphylactic and anaphylactoid reactions due to anesthetic agents. *Clin Rev Allergy* 4:215-227, 1986
- Fisher MM: Direct histamine release in anaesthesia and surgery: unanswered questions. *Theor Surg* 3:145-147, 1988
- Reilly CS, Nimmo WS: New intravenous anaesthetics and neuromuscular blocking drugs. A review of their properties and clinical use. *Drugs* 34:98-135, 1987
- Langley MS, Heel RC: Propofol A review of its pharmacodynamics and pharmacokinetic properties and use as an intravenous anaesthetic. *Drugs* 35:334-372, 1988
- Kanto JH: Propofol, the newest induction agent of anesthesia. *International J Clin Pharmacol Ther Toxicol* 26:41-57, 1988
- Briggs LP, Clarke RSJ, Watkins J: An adverse reaction to the administration of disopropofol (Diprivan). *Anaesthesia* 37:1099-1101, 1982
- Watkins J; Tests *in vivo* and *in vitro* of hypersensitivity response, Guide to immediate anaesthetic reactions. Edited by Watkins J. London, Butterworths, 1988, pp. 101-115
- McBride P, Bradley D, Kaliner M: Evaluation of a radioimmunoassay for histamine measurement in biologic fluids. *Clin Immunol* 82:638-646, 1988
- Glen JB, Hunter SC: Pharmacology of an emulsion formation of ICI 35858. *Br J Anaesth* 56:617-626, 1984
- Doenicke A, Lorenz W, Stanworth D, et al: Effects of propofol ('Diprivan') on histamine release, immunoglobulin levels and activation of complement in healthy volunteers. *Postgrad Med J* 61 (Suppl. 3):15-20, 1985
- Dudziak R, Förster H, Hoffmann E, et al: Das Verhalten des Histaminspiegels während der Einleitung der Anaesthesie mit Propofol und Methohexital. *Anaesthesist* 36:412-419, 1987
- Lorenz W, Meyer R, Doenicke A, et al: On the species specificity of the histamine release from mast cell stores by cremophor-EL. *Naunyn-Schmiedeberg's Arch Pharmacol* 269:417-418, 1971
- Laxenaire MC, Khameh L, Heravi Z, et al: Histaminolibération non spécifique et propofol. *Ann Fr Anesth Réanim* 6:230-232, 1987
- Widmer S, Laxenaire MS, Manel J, et al: Étude du pouvoir histaminolibérateur *in vivo* des hypnotiques (thiopental, méthohexital, propofol) par dosages d'histamine plasmatique. *Allerg Immunol* 20:346-347, 1988
- Withington DE: Basophil histamine release studies in the evaluation of a new anaesthetic agent. *Agents Actions* 23:337-338, 1988
- Williamson J: Safe induction with propofol following thiopentone anaphylaxis. *Anesth Inten Care* 18:277-228, 1990
- Laxenaire MC, Gueant JL, Bermejo E, et al: Anaphylactic shock due to propofol. *Lancet* 2:739-740, 1988
- Mouton C, Mata E, Gerrard P, et al: Premier cas de choc anaphylactique au propofol, agent anesthésique récent. *Ann Med Nancy et de L'est* 29:47, 1990

19. Nauquib M: Anaphylactoid reactions following propofol-atracurium sequence. *Can J Anesth* 36:358-366, 1989